(Q36066200)

12 August 2017

1 reference

title

Ertapenem: review of a new carbapenem (English)

1 reference

12 August 2017

main subject

carbapenem antibiotic

0 references

1

George G Zhanel

1 reference

12 August 2017

Christel Johanson

2

1 reference

12 August 2017

John M Embil

3

1 reference

12 August 2017

Ayman Noreddin

4

1 reference

12 August 2017

Alfred Gin

5

1 reference

12 August 2017

Lavern Vercaigne

6

1 reference

12 August 2017

Daryl J Hoban

7

1 reference

12 August 2017

publication date

1 February 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

3

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

23-39

1 reference

The carbapenems: new broad spectrum beta-lactam antibiotics

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Recent developments in carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Carbapenems in Pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Neurotoxicity of carbapenem antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem, the first of a new group of carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem: a review of its use in the management of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative pharmacokinetics of the carbapenems: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Properties and potential of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem: a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro activity of ertapenem: review of recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Activity of ertapenem against Neisseria gonorrhoeae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Pharmacokinetics of ertapenem in healthy young volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Pharmacokinetics of intramuscularly administered ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem therapy for community-acquired pneumonia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Surgical Infections withEnterococcus: Outcome in Patients Treated with Ertapenem versus Piperacillin-Tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Safety and tolerability of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem versus Piperacillin-Tazobactam for Treatment of Mixed Anaerobic Complicated Intra-Abdominal, Complicated Skin and Skin Structure, and Acute Pelvic Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro activity of ertapenem against bacterial isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro antimicrobial activity of doripenem, a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.23

21 January 2018

Identifiers

DOI

10.1586/14787210.3.1.23

1 reference

12 August 2017

1 reference